Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2017 Nov 10;121(11):1213-1215.
doi: 10.1161/CIRCRESAHA.117.312074.

Posology for Regenerative Therapy

Andre Terzic  1 , Atta Behfar  2
Affiliations
Editorial

Posology for Regenerative Therapy

Andre Terzic et al. Circ Res. .
No abstract available

Keywords: Editorials; biologics; clinical trial; heart failure; pharmacology; regenerative medicine; stem cells.

PubMed Disclaimer

Figures

Figure
Figure. Linking elements that determine the posology paradigm for regenerative therapy
Regenerative biotherapies display complex pharmacodynamics and pharmacokinetics encompassing multiple factors including the delivery method and intensity, the biotherapeutics type and behavior, and the patient demographics and disease substrate.
See this image and copyright information in PMC

Comment on

  • Dose Comparison Study of Allogeneic Mesenchymal Stem Cells in Patients With Ischemic Cardiomyopathy (The TRIDENT Study).
    Florea V, Rieger AC, DiFede DL, El-Khorazaty J, Natsumeda M, Banerjee MN, Tompkins BA, Khan A, Schulman IH, Landin AM, Mushtaq M, Golpanian S, Lowery MH, Byrnes JJ, Hendel RC, Cohen MG, Valasaki K, Pujol MV, Ghersin E, Miki R, Delgado C, Abuzeid F, Vidro-Casiano M, Saltzman RG, DaFonseca D, Caceres LV, Ramdas KN, Mendizabal A, Heldman AW, Mitrani RD, Hare JM. Florea V, et al. Circ Res. 2017 Nov 10;121(11):1279-1290. doi: 10.1161/CIRCRESAHA.117.311827. Epub 2017 Sep 18. Circ Res. 2017. PMID: 28923793 Free PMC article. Clinical Trial.

Similar articles

See all similar articles

Cited by

References

    1. Musuamba FT, Manolis E, Holford N, Cheung S, Friberg LE, Ogungbenro K, Posch M, Yates J, Berry S, Thomas N, Corriol-Rohou S, Bornkamp B, Bretz F, Hooker AC, Van der Graaf PH, Standing JF, Hay J, Cole S, Gigante V, Karlsson K, Dumortier T, Benda N, Serone F, Das S, Brochot A, Ehmann F, Hemmings R, Rusten IS. Advanced methods for dose and regimen finding during drug development. CPT Pharmacometrics Syst Pharmacol. 2017;6:418–429. - PMC - PubMed
    1. Marks PW, Witten CM, Califf RM. Clarifying stem-cell therapy’s benefits and risks. N Engl J Med. 2017;376:1007–1009. - PubMed
    1. Fujita Y, Kawamoto A. Regenerative medicine legislation in Japan for fast provision of cell therapy products. Clin Pharmacol Ther. 2016;99:26–29. - PubMed
    1. Fisher SA, Doree C, Mathur A, Martin-Rendon E. Meta-analysis of cell therapy trials for patients with heart failure. Circ Res. 2015;116:1361–1377. - PubMed
    1. Golpanian S, Schulman IH, Ebert RF, Heldman AW, DiFede DL, Yang PC, Wu JC, Bolli R, Perin EC, Moyé L, Simari RD, Wolf A, Hare JM, Cardiovascular Cell Therapy Research Network Review and perspective of cell dosage and routes of administration from preclinical and clinical studies of stem cell therapy for heart disease. Stem Cells Transl Med. 2016;5:186–191. - PMC - PubMed